ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

The Health Benefits of Manuka Honey

Increase Your Magnesium Intake

Vitamin D supplementation could ease IBS symptoms

Top Tips to Boost Your Immunity

11 Amazing Health Benefits of Using Baking Soda

Nicotinamide riboside shows promise for treatment of Alzheimer’s disease

Exercise, calcium, vitamin D, and other factors linked with fewer injurious falls

Vitamin D3 Is a Powerhouse for Your Heart

Curcumin Supplementation May Impart Long-Term Cognitive Benefits

Rhodiola — A Powerful Adaptogen That Boosts Vitality and Performance, Eases Depression and Combats B...

 
Print Page
Email Article

Tribunal Orders Release of PACE Data

  [ 22 votes ]   [ 2 Comments ]
By Alex Anderssen • www.ProHealth.com • August 24, 2016


Tribunal Orders Release of PACE Data
Reprinted with the kind permission of Alex Anderssen and MEAction.

By Alex Anderssen

A tribunal panel has ordered Queen Mary University of London (QMUL) to release anonymised data from the PACE trial to Mr. Alem Matthees, a patient who requested it. The ruling has important implications for CFS patients both in the UK and worldwide.

The David-vs-Goliath outcome represents the first successful attempt to begin to counter the PACE authors’ claims — believed by many scientists and thousands of patients to be highly questionable — that the PACE trial showed graded exercise and cognitive therapy to be effective treatments for CFS.

The tribunal was held in April in London, and the panel heard three days of evidence on QMUL’s appeal against the UK Information Commissioner’s decision that they must release the data. Mr. Matthees had requested the data in March 2014 under the Freedom of Information Act, to allow him to conduct main outcome and recovery analyses specified in PACE’s own protocol but abandoned during the trial.

Mr. Tom Kindlon, a patient who has published criticism of the PACE trial in medical journals, said, “This is a huge victory for patients, who have a right to examine the evidence for the treatments that affect their lives. I expect that the recovery rate will only be a small fraction of what they claimed, due to the dramatic changes they made to the criteria.”

The tribunal’s decision-document summarises the evidence given at the hearing and includes the tribunal panel’s commentary. For example, the document notes Mr. Matthees’s concern that QMUL were restricting the researchers to whom they would provide data upon request, and states, “The evidence before us is not clear but if QMUL are cherry­picking who analyses their data from within the recognised scientific research sphere to only sympathetic researchers, there could be legitimate concerns that they wish to suppress criticism and proper scrutiny of their trial”.

The document summarised the Information Commissioner’s comments on the testimony of Professor Ross Anderson, one of QMUL’s witnesses, who gave evidence on data security. The tribunal panel noted that the Commissioner had referred to Professor Anderson’s “wild speculations” that “young men, borderline sociopathic or psychopathic” would attempt to identify trial participants from the anonymised data, and said that his views “do him no credit”.

The panel wrote that Professor Anderson’s assessment of activist behaviour was “grossly exaggerated and the only actual evidence was that an individual at a seminar had heckled Professor Chalder”. The report noted the Information Commissioner’s view that Professor Chalder, who is one of PACE’s principal investigators, “accepts that unpleasant things have been said to and about PACE researchers only, but that no threats have been made either to researchers or participants”.

The panel added, “The identity of those questioning the research, who had signed an open letter or supported it, was impressive.”
QMUL spent over £200,000 in making the appeal. A further appeal is possible but only on the grounds the law has been interpreted incorrectly or the wrong law applied, rather than on the facts of the case.

Science blogger Simon McGrath said, “The State, and taxpayers, ultimately fund clinical research for the benefit of patients, so it’s important patients get accurate, reliable information on the effectiveness of any tested treatments. And researchers should not, in my view, go to such lengths to hide their data from scrutiny: it might be in their interests, it’s not in the interests of patients.”

Trevor Butterworth, the Director of Sense About Science USA, said in response to the news, “The PACE trial is a fault line between the way we did medicine (secretive, clubbable) and the way we should do medicine (transparent, shared).”

The PACE paper, as it stands in The Lancet, includes an analysis in which patients’ physical function could worsen during the trial to approximately the average level of Class II congestive heart failure patients and yet they would be considered to have been effectively treated. The Lancet has ignored requests to issue a correction notice.

However, independent analysis of the released raw data would allow researchers to bypass The Lancet and publish the more appropriate, protocol-specified analyses elsewhere. Such reanalyses are likely to revise estimates of the effectiveness of graded exercise and cognitive behavioural therapy considerably downwards. This would also put pressure on the UK’s National Institute for Healthcare and Clinical Excellence (NICE) to review its NHS treatment guidelines, which currently recommend these therapies for CFS.

In related news, in response to requests by US patient organizations and advocates, the Agency for Healthcare Research and Quality (AHRQ) has issued an Addendum to its 2014 ME/CFS evidence review. This Addendumdowngrades the conclusions on the effectiveness of cognitive behavioral therapy (CBT) and graded exercise therapy (GET) to state that there is not good evidence of effectiveness in ME or ME/CFS patients.  Read more about this development here.






Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Optimized Curcumin Longvida® Ultra ATP+, Double Strength


Article Comments Post a Comment

AntiRetrovirals vs Pace/Lipkin
Posted by: SpartaK
Aug 24, 2016
An exogenous replicating pathogenic retrovirus was identified in Melvin Ramsey defined ME by way of the equivalent modern day rigourous CCC Canadian criteria in a paper published by Dr Judy Mikovits and leading HIV/HTLV researcher Francis Ruscetti in Science in 2009.

Insufficient replication attempts including a definitive mbio 2012 Lipkin led paper failed to do justice to the complexity of the original 2009 paper which remains Top Flight upper echelon research.There are credible reasons according to one or two authors of that mbio 2012 Lipkin paper to believe that the 2012 paper was fraud in hindsight.

I am better on 245mg Viread and 800mg Raltegravir for the Myalgic Encephalomyelitis defined above, four days per week on those antiretroviral medications. A few of us have called the bluff of Lipkin and of the Pace Trial authors too..

Game is up guys. We got you. All of you. Shame on you all. We did everything but fold faced with your intimidation and bullying keeping us all sick for so long while you tended to the fatigued and made this illness out to be something it is not to include more patients and to dilute it and confuse it with psychology and bogus overlapping fatigue word clinical state markers and your faked compassion, tv shows et cetera.

All in. Viread, Raltegravir chips All In. Hear it well. Just finally LISTEN to us. That is all. We called your bluffs - elite virologist hunters and psychiatrists. Game is up now.

Just like HIV patients we are learning how best to take the medications and getting there. Sometimes failing on them, as do the HIV patients. Sometimes winning, as do the HIV patients.
But learning, just like the HIV patients, over time, how best to take them, retake them, and over time winning and getting better with antiretrovirals and other immune modulating drugs given in HIV and related disease.

It's a RETROVIRUS. 30 years on from HIV. Deal with it.
Reply Reply

Help the afflicted and incarcerate the swindlers.
Posted by: headsails
Aug 24, 2016
It's good to see the empirically valid patients coming first and not the back-room-swindler-Dr-Corporate-crony-Money-Clubs. Whenever the medical establishment is at odds about something they can't explain, they default to the standard "graded exercise and cognitive therapy" BS. It's not different than when it was thought that masturbation caused blindness. It really is that moronic of an excuse and is treated like it's some kind of super-science worthy of respect. It's like they have to say something that sounds half way intelligent or else be found out for the frauds that they really are; paid-for academic stooges for their corporate masters. If we only knew the back stabbing and injustices that are happening around ME, they would need more room up in the Tower of London to keep them shackled.
Reply Reply
 
Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World
When a Good Night's Sleep Is Just a Daydream... When a Good Night's Sleep Is Just a Daydream...
The Fibromyalgia and Glutathione Link The Fibromyalgia and Glutathione Link
Three-Step Strategy to Reverse Mitochondrial Aging Three-Step Strategy to Reverse Mitochondrial Aging

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map